DCC license conversions after rescheduling: how and when to split A/M licenses in California

When obtaining a California cannabis licenses, operators had to decide whether to operate under an adult-use license, a medicinal license, or a combined A/M structure. However, what once looked like a routine licensing question with a simple answer now affects tax planning, federal compliance, and supply-chain viability. For some businesses, converting or splitting licenses may help align their operations with Schedule III medical activity and better 280E positioning. For others, rushing into a conversion could create new compliance problems.

Why license structure matters now

The federal government’s April 2026 rescheduling action created a path for qualifying medical cannabis activity to move outside the full reach of Internal Revenue Code Section 280E. Adult-use activity, however, remains subject to the same punitive tax treatment. That makes the distinction between medical cannabis and adult-use cannabis more important than before.

Many businesses have treated A, M, and combined A/M designations as mostly administrative. After rescheduling, those choices may affect whether a company can credibly position part of its business as medical, whether it can support a future DEA registration, and whether its books and records can sustain a defensible allocation between medical and adult-use activity.

What changed under the DCC rules

As mentioned in our prior post, the DCC’s 2026 emergency regulations allow operators to revisit license designations outside the annual renewal cycle and restructure existing operations more easily. For businesses holding combined A/M licenses, that creates an opportunity to separate adult-use and medicinal activity more clearly and efficiently.

In the right case, a cleaner split can support better accounting, stronger compliance controls, and a more coherent medical-only posture.

Why some operators should consider conversion or splitting

The strongest reason is tax planning. If a meaningful part of the business may qualify as medical under the new federal framework, a clearer medicinal structure may help support that position. That does not guarantee 280E relief, but it puts the operator in a better position than a business trying to claim medical treatment while maintaining a blurred structure.

Operators considering DEA registration should be asking whether their business actually looks like a medical operation. A separate medicinal license, distinct inventory controls, and medical-specific procedures can bolster your position.

A distinct medicinal structure may also help with patient branding, financings, or sale transactions where buyers want cleaner separation between medical and adult-use operations.

The supply-chain issue operators cannot ignore

If a retailer wants to truly create a split between its medical and adult-use operation, the same logic should apply upstream: cultivators, manufacturers, and distributors should also have an isolated medical license or a medical operation clearly separate from adult-use activity. A strategy for a medicinal retailer is harder to defend if the product moves through businesses that blur medical and adult-use operations at every step along the supply chain.

This creates a chain-wide segregation issue. A retailer may split its licenses, but if cultivators, distributors, or manufacturers do not separate medical product, maintain distinct records, and structure their licenses accordingly, the medical model may exist only at the point of sale. That weakens both the compliance and the tax posture as a medical-only operation.

For California businesses, conversion analysis should include a full supply-chain audit. Before restructuring around a medical-only strategy, operators should identify which partners down the supply chain can support a separate medical channel and which cannot. If the answer is very few, a premature conversion may create complexity without much benefit.

Common pitfalls

The first mistake is treating conversion as purely a tax move. Yes, 280E matters, but weak operations can turn a good theory into audit risk. The second mistake is assuming a medicinal license alone solves the DEA issue. It does not; federal alignment depends on how the business actually operates and how product moves through the supply chain.

Another common problem is failing to align local permits, leases, and vendor contracts with the new structure.

Who should move now, and who should wait

Operators with real medical patient volume, serious interest in DEA registration, and a supply chain that can align with the medical only framework are the strongest candidates for immediate action. The same is true for businesses preparing for financing, sale, or restructuring.

By contrast, purely adult-use retailers with little medical demand may be better off waiting. So may businesses whose suppliers lack medical operations, and businesses that lack the internal systems needed to support clean separation of medical and adult-use activity.

Practical next steps

Before pursuing a conversion or split, licenses California cannabis businesses should ask:

• Does the business have enough genuine, medical cannabis activity to justify a medicinal strategy?
• Can accounting, inventory, and SOPs support a defensible separation between medical and adult-use activity?
• Is the supply chain capable of moving toward medical cannabis only?
• Do local permits, leases, and contracts support the proposed change?

If the answers are favorable, a conversion may be worth pursuing now. If not, prepare first and file later. Businesses most likely to benefit from rescheduling will treat licensing, tax, and supply-chain analysis as one strategy.

 

DCC License Conversions After Rescheduling: How and When to Split A/M Licenses in California